ACC.26 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined onsite by principal investigator Dr Wayne Batchelor (Inova Schar Heart and Vascular, US) to discuss the ALERT trial.  

ALERT is a pragmatic, multicentre, cluster-randomised study evaluating the Tempus Next platform, which continuously scans echocardiography reports to identify patients with severe aortic stenosis or mitral regurgitation and sends targeted automated EHR alerts to their clinicians to prompt timely specialist review. The trial enrolled just over 2,000 patients across multiple US health systems and tests whether these notifications increase the proportion of patients receiving valve intervention or multidisciplinary heart-team assessment within 90 days, with prespecified analyses focusing on under-treatment and disparities by sex, race, ethnicity and geography. The rationale for ALERT is the persistent real-world gap whereby many patients with severe valve disease, particularly women, minority populations and those in rural settings, fail to receive timely guideline-directed structural interventions despite the availability of effective transcatheter and surgical therapies.  

Editor: Mirjam Boros  
Video Specialist: Tom Green

Support: This is an independent discussion produced by Radcliffe Cardiology.  

For more expert insights and late-breaking science from ACC 2026, visit the Late-breaking Science Video Collection.